

# Allergic Rhinitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/ABF409789BA9EN.html>

Date: May 2024

Pages: 130

Price: US\$ 6,499.00 (Single User License)

ID: ABF409789BA9EN

## Abstracts

The 7 major allergic rhinitis markets reached a value of US\$ 3,610.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 5,078.0 Million by 2034, exhibiting a growth rate (CAGR) of 3.15% during 2024-2034.

The allergic rhinitis market has been comprehensively analyzed in IMARC's new report titled "Allergic Rhinitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Allergic rhinitis, or hay fever, is a type of nasal inflammation caused by the immune system overreacting to allergens in the air. This reaction causes the mucous membrane of the nose to release a variety of chemicals, causing the nose to swell and produce an excessive amount of mucus. Some of the common symptoms are sneezing, nasal congestion, clear rhinorrhea, nasal pruritus, postnasal drip, etc. Individuals suffering from allergic rhinitis may also experience conjunctival swelling and erythema, lower eyelid venous stasis, eyelid swelling, middle ear effusion, swollen nasal turbinates, etc. The diagnosis of allergic rhinitis typically involves a combination of patient history, physical examination, and allergy testing. Medical history and physical examination can provide information on the duration and frequency of symptoms, as well as any associated conditions, such as asthma. Allergy testing may involve skin prick tests or blood tests to identify specific allergens triggering the allergic reaction. Various additional investigations, including nasal endoscopy, may be performed to rule out other potential causes of symptoms.

The increasing prevalence of allergic reactions to various allergens, such as pollen, pet dander, dust mites, mold, etc., is primarily driving the allergic rhinitis market. Moreover, the escalating utilization of topical nasal corticosteroids, since they aid in reducing inflammation in the nasal passages and alleviate symptoms, including congestion,

sneezing, runny nose, etc., is also bolstering the market growth. Besides this, the widespread adoption of rhinomanometry, which measures the resistance of airflow through the nasal passages to identify any blockages or narrowing that may be causing the ailment, is acting as another significant growth-inducing factor. Additionally, the ongoing development of advanced drug delivery systems, such as nasal sprays and inhalers, is improving the efficacy and convenience of treatment for allergic rhinitis patients, thereby propelling the market growth. Furthermore, the rising application of the basophil activation test, which reduces the need for in-vivo procedures and specifically detects all the characteristics of IgE and allergens in the diagnosis of allergic disease, is positively influencing the market. Apart from this, the emerging popularity of sublingual allergen immunotherapy owing to its several associated benefits, including ease of self-administration and reduced risk for systemic reactions, is expected to drive the allergic rhinitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the allergic rhinitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for allergic rhinitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the allergic rhinitis market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the allergic rhinitis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the allergic rhinitis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current allergic rhinitis marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the allergic rhinitis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the allergic rhinitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the allergic rhinitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of allergic rhinitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of allergic rhinitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of allergic rhinitis by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of allergic rhinitis by type across the seven major markets?

How many patients are diagnosed (2018-2034) with allergic rhinitis across the seven major markets?

What is the size of the allergic rhinitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of allergic rhinitis?

What will be the growth rate of patients across the seven major markets?

### Allergic Rhinitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for allergic rhinitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the allergic rhinitis market?

What are the key regulatory events related to the allergic rhinitis market?

What is the structure of clinical trial landscape by status related to the allergic rhinitis market?

What is the structure of clinical trial landscape by phase related to the allergic rhinitis market?

What is the structure of clinical trial landscape by route of administration related to the allergic rhinitis market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 ALLERGIC RHINITIS - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 ALLERGIC RHINITIS - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 ALLERGIC RHINITIS - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Epidemiology by Type (2018-2034)
  - 7.2.6 Diagnosed Cases (2018-2034)
  - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Epidemiology by Type (2018-2034)
  - 7.3.6 Diagnosed Cases (2018-2034)
  - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Epidemiology by Type (2018-2034)
  - 7.4.6 Diagnosed Cases (2018-2034)
  - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Epidemiology by Type (2018-2034)
  - 7.5.6 Diagnosed Cases (2018-2034)
  - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Epidemiology by Type (2018-2034)
  - 7.6.6 Diagnosed Cases (2018-2034)

- 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)
  - 7.7.4 Epidemiology by Gender (2018-2034)
  - 7.7.5 Epidemiology by Type (2018-2034)
  - 7.7.6 Diagnosed Cases (2018-2034)
  - 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Epidemiology by Type (2018-2034)
  - 7.8.6 Diagnosed Cases (2018-2034)
  - 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Epidemiology by Type (2018-2034)
  - 7.9.6 Diagnosed Cases (2018-2034)
  - 7.9.7 Patient Pool/Treated Cases (2018-2034)

## **8 ALLERGIC RHINITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 ALLERGIC RHINITIS - UNMET NEEDS**

## **10 ALLERGIC RHINITIS - KEY ENDPOINTS OF TREATMENT**

## **11 ALLERGIC RHINITIS - MARKETED PRODUCTS**

- 11.1 List of Allergic Rhinitis Marketed Drugs Across the Top 7 Markets



- 11.1.1 Odactra (House dust mite allergy immunotherapy) - ALK-Abello
  - 11.1.1.1 Drug Overview
  - 11.1.1.2 Mechanism of Action
  - 11.1.1.3 Regulatory Status
  - 11.1.1.4 Clinical Trial Results
  - 11.1.1.5 Sales Across Major Markets
- 11.1.2 Grastek (Grass pollen allergy vaccine tablet) - ALK-Abello
  - 11.1.2.1 Drug Overview
  - 11.1.2.2 Mechanism of Action
  - 11.1.2.3 Regulatory Status
  - 11.1.2.4 Clinical Trial Results
  - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Clarinex (Desloratadine) - Merck & Co
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Astelin (Azelastine) - Meda
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Xyzal (Levocetirizine) - Sanofi-Aventis/UCB
  - 11.1.5.1 Drug Overview
  - 11.1.5.2 Mechanism of Action
  - 11.1.5.3 Regulatory Status
  - 11.1.5.4 Clinical Trial Results
  - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 ALLERGIC RHINITIS - PIPELINE DRUGS**

- 12.1 List of Allergic Rhinitis Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 IRL 201104 - Revolo Biotherapeutics
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action

- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status
- 12.1.2 REGN5713 5714 5715 - Regeneron Pharmaceuticals
  - 12.1.2.1 Drug Overview
  - 12.1.2.2 Mechanism of Action
  - 12.1.2.3 Clinical Trial Results
  - 12.1.2.4 Safety and Efficacy
  - 12.1.2.5 Regulatory Status
- 12.1.3 Grass MATA MPL - Allergy Therapeutics
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 MM09 - Immunotek
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. ALLERGIC RHINITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. ALLERGIC RHINITIS – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 ALLERGIC RHINITIS - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Allergic Rhinitis - Market Size

- 15.2.1.1 Market Size (2018-2023)
- 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Allergic Rhinitis - Market Size by Therapies
  - 15.2.2.1 Market Size by Therapies (2018-2023)
  - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Allergic Rhinitis - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Allergic Rhinitis - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Allergic Rhinitis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Allergic Rhinitis - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Allergic Rhinitis - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Allergic Rhinitis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Allergic Rhinitis - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Allergic Rhinitis - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Allergic Rhinitis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Allergic Rhinitis - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Allergic Rhinitis - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Allergic Rhinitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Allergic Rhinitis - Market Size

- 15.7.1.1 Market Size (2018-2023)
- 15.7.1.2 Market Forecast (2024-2034)
- 15.7.2 Allergic Rhinitis - Market Size by Therapies
  - 15.7.2.1 Market Size by Therapies (2018-2023)
  - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Allergic Rhinitis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Allergic Rhinitis - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Allergic Rhinitis - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Allergic Rhinitis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Allergic Rhinitis - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Allergic Rhinitis - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Allergic Rhinitis - Access and Reimbursement Overview

## **16 ALLERGIC RHINITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 ALLERGIC RHINITIS MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 ALLERGIC RHINITIS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Allergic Rhinitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/ABF409789BA9EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ABF409789BA9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

